@article {Murphy2020.06.28.20142042, author = {Nicholas Murphy and Alison Killen and Sara Graziadio and Lynn Rochester and Michael Firbank and Mark R Baker and Charlotte Allan and Daniel Collerton and John-Paul Taylor and Prabitha Urwyler}, title = {Exploring Bottom-Up Visual Processing and Visual Hallucinations in Parkinson{\textquoteright}s Disease with Dementia}, elocation-id = {2020.06.28.20142042}, year = {2020}, doi = {10.1101/2020.06.28.20142042}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Visual hallucinations (VH) are a common symptom of Parkinson{\textquoteright}s disease with dementia (PDD), affecting up to 65\% of cases. Integrative models of their etiology posit that a decline in executive control of the visuo-perceptual system is a primary mechanism of VH generation. The role of bottom-up processing in the manifestation of VH in this condition is still not clear. Here we compared amplitude and latency patterns of reversal visual evoked potentials (VEPs) in healthy controls (n=21) and PDD patients (n = 34) with a range of VH severities. PDD patients showed increased N2 latency relative to controls, but patients reporting complex VH (n=17) did not demonstrate any relationship between VEP measurements and their hallucination severity as measured on the neuropsychiatric inventory hallucinations subscale (NPIHal) score. Our VEP findings support previous reports of declining visual system physiology in PDD. However, no notable major relationships between the integrity of the visual pathway and VH were found.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe research was supported by a Swiss National Science Foundation grant (IZK0Z3_173146) to PU and by National Institute for Health Research (NIHR) Newcastle Biomedical Research Centre (BRC) based at Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University. SG was funded by the NIHR MedTech In Vitro Diagnostics Co-operative scheme (ref MIC-2016-014).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was granted by the Newcastle National Health Service (NHS) Health Research Authority (HRA) (REC reference: 13/NE/0252; R\&D reference: 6691).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData pertaining to the obtained results may be provided upon request.}, URL = {https://www.medrxiv.org/content/early/2020/06/29/2020.06.28.20142042}, eprint = {https://www.medrxiv.org/content/early/2020/06/29/2020.06.28.20142042.full.pdf}, journal = {medRxiv} }